ENTA News and Press, Enanta Pharmaceuticals Inc. From 05/08/23

Study Met Primary Endpoints of Safety and Tolerability Dose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to Placebo, Achieving Statistical Significance as Early as One Day After First Dose No Difference in Viral Load Reduction; Rapid Declin...

Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19 Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET ® /MAVIRET ® Royalties for an Up...

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2023 after the U.S. market closes on ...

Preclinical Data Demonstrate EDP-235’s Superior Target Tissue Distribution and Cell Penetration Compared to Other Protease Inhibitors New Preclinical Pharmacokinetic Data Highlight EDP-323’s Strong Bioavailability and Favorable Tissue Targeting Enanta Pharmaceu...

2023-04-06 07:25:43 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Enanta Pharmaceuticals' ( NASDAQ: ENTA ) EDP-323 to treat respiratory syncytial virus (RSV). The company is evaluating EDP-323 in a phase 1 trial and expects to report topline ...

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibit...

Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and ED...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

2023-03-10 21:26:19 ET Several smaller pharma and biotech companies have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). The biotech was the biggest exposure disclosed so far is Sangamo Therapeutics ( NASDAQ: SGMO ), with $34.4M in ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presen...